Analyst Ratings for Spruce Biosciences
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 6 analysts have published their opinion on Spruce Biosciences (NASDAQ:SPRB) stock. The analysts have an average price target of $8.67 versus the current price of Spruce Biosciences at $2.36, implying upside. This current average has increased by 44.5% from the previous average price target of $6.00.
September 08, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts predict a potential upside for Spruce Biosciences, with an average price target of $8.67, which is significantly higher than its current price of $2.36.
The average price target set by analysts indicates a potential upside for the stock. This is a positive signal as it shows that analysts believe the stock is undervalued at its current price. The increase in the average price target from the previous one also suggests that analysts have become more bullish on the stock over the past 3 months.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100